×
ADVERTISEMENT

MAY 23, 2025

Just a Phase

New Trials Suggest Promising Treatment Pipeline for MASH and MASLD


Originally published by our sister publication Gastroenterology & Endoscopy News

By Jillian Mock

SAN DIEGO—The results of several studies presented at The Liver Meeting 2024 suggest there is a robust treatment pipeline for metabolic dysfunction–associated steatohepatitis and metabolic dysfunction–associated steatotic liver disease.

“These are exciting times in the field of MASLD/MASH, with a very promising pipeline of pharmacotherapies in development,” said Bubu